Sangui Biotech International Inc (SGBI) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SGBI Annual Balance Sheets →
Tracking balance sheet results across Sangui Biotech International Inc to Mar 31 2022 helps illustrate how Mar 31 2023's financial position has responded to changing business conditions.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2023)
(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Assets
Cash & cash equivalent0.01
Cash & Short-term Investments0.00
Accounts receivable0.00
Due from Related Parties, Current RE0.00
Other Current Assets0.01
Prepaid Expense, Current AS0.02
Total Current Assets0.04
Equipment/Property/Plant Net0.05
Other Assets, Noncurrent0.00
Total Assets0.09
Liabilities
Accounts Payable and Other Accrued Liabilities, Current0.18
Short-term Debt0.73
Other Liabilities, Current0.12
Taxes Payable, Current, Total0.00
Total Current Liabilities1.03
Long-term debt0.04
Total Long-term Debt0.04
Other liabilities, Noncurrent0.03
Total Liabilities1.10
Stockholders' Equity
Common Stock Value33.12
Additional Paid In Capital Common Stock4.51
Retained Earnings / Accumulated Deficit-38.07
Other Equity0.08
Common Stockholder's Equity-0.35
Non-controlling interests & other-0.66
Total Stockholder's Equity-1.01
Liabilities & Stockholder's Equity0.09
4 historic quarters locked

Sign in to unlock the full Sangui Biotech International Inc balance sheet history.

About Sangui Biotech International Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001096906-23-001042

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.